Therapeutic eVect of intratumoral administration of DCs with conditional expression of combination of diVerent cytokines

Cancer Immunology, Immunotherapy

Volumn 61, Issue 4, 2012, Pages 573-579

  Huang, Chun ^a,b   Ramakrishnan, Rupal ^a   Trkulja, Marko ^a   Ren, Xiubao ^b   Gabrilovich, Dmitry I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer immunotherapy; Dendritic cells; IFN ; IL 12; IL 21

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; DENDRITIC CELL VACCINE; INTERLEUKIN 12; INTERLEUKIN 21; CYTOKINE; INTERLEUKIN DERIVATIVE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ADMINISTRATION ROUTE; DRUG CYTOTOXICITY; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; FIBROSARCOMA; GENE EXPRESSION SYSTEM; KIDNEY CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEOSWITCH THERAPEUTIC SYSTEM; SINGLE DRUG DOSE; TUMOR ASSOCIATED LEUKOCYTE; VIRAL GENE DELIVERY SYSTEM; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DENDRITIC CELL; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; PATHOLOGY; SARCOMA; SKIN TUMOR; TRANSGENE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; INTERLEUKIN-12; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; SARCOMA; SKIN NEOPLASMS; TRANSGENES;

EID: 84862489428     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1198-9     Document Type: Article

References (28)

1. Chen YZ, Yao XL, Tabata Y, Nakagawa S, Gao JQ (2010) Gene carriers and transfection systems used in the recombination of dendritic cells for eVective cancer immunotherapy. Clin Dev Immunol 2010:565643
2. Butterfield LH, Vujanovic L (2010) New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Curr Opin Investig Drugs 11(12):1399-1408
3. Kumar P, Katakam A (2007) Rheoswitch system: a highly sensitive ecdysone receptro-based gene regulation system induced by synthetic small-molecule ligands. In: Friedman T, Rossi J (eds) Gene transfer: delivery and expression of DNA and rna. Cold Spring Harbor Laboratory Press, NY, pp 643-651
4. Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, Carbone DP (1999) Dendritic cells transduced with wild type p53 gene elicit potent antitumor immune responses. Clin Exp Immunol 117:244-251 (Pubitemid 29343594)
5. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449(7161):419-426 (Pubitemid 47509552)
6. Larocca C, Schlom J (2011) Viral vector-based therapeutic cancer vaccines. Cancer journal (Sudbury, Mass 17 (5):359-371
7. Candido KA, Shimizu K, McLaughlin JC, Kunkel R, Fuller R, Redman BG, Thomas EK, NickoloV BJ, Mule JJ (2001) Local administration of dendritic cells inhibits established breast tumor growth: implication for apoptosis-inducing agents. Cancer Res 61:228-236 (Pubitemid 32095722)
8. Nikitina EY, Gabrilovich DI (2001) Combination of gamma irradiation and dendritic cell administration in treatment of advanced cancer. Intern J Cancer 94:825-833
9. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, McGinn CJ, Chang AE (2003) Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 63:8466-8475 (Pubitemid 37549503)
10. Yu B, Kusmartsev S, Cheng F, Paolini M, Nefedova Y, Sotomayor E, Gabrilovich D (2003) EVective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 9:285-294 (Pubitemid 36109745)
11. Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI (2012) Combination of external beam radiotherapy (ebrt) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys [Epub ahead of print]
12. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL (2005) Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 28(2):129-135 (Pubitemid 40328199)
13. Mann DL, Celluzzi CM, Hankey KG, Harris KM, Watanabe R, Hasumi K (2009) Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated t cells to treat patients with advanced cancers. Ann N Y Acad Sci 1174:41-50
14. Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, Braughler JM, Storkus WJ (2009) Conditional interleukin-12 gene therapy promotes safe and eVective antitumor immunity. Cancer Gene Ther 16(12):883-891
15. Qu Y, Taylor JL, Bose A, Storkus WJ (2011) Therapeutic eVectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (il)-32. Cancer Gene Ther 18(9):663-673
16. Kayashima H, Toshima T, Okano S, Taketomi A, Harada N, Yamashita Y, Tomita Y, Shirabe K, Maehara Y (2010) Intratumoral neoadjuvant immunotherapy using il-12 and dendritic cells is an eVective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice. J Immunol 185(1):698-708
17. Gabrilovich DI, Cunningham HT, Carbone DP (1997) Il-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J Immunother 19:414-418
18. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162-174
19. Steding CE, Wu ST, Zhang Y, Jeng MH, Elzey BD, Kao C (2011) The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 133(2):221-238
20. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy of cancer by il-12-based cytokine combinations. Expert Opin Biol Ther 7(11):1705-1721 (Pubitemid 350157496)
21. + t lymphocytes. J Immunol 178(2):732-739. doi:178/2/732
22. Williams P, Bouchentouf M, Rafei M, Romieu-Mourez R, Hsieh J, Boivin MN, Yuan S, Forner KA, Birman E, Galipeau J (2010) A dendritic cell population generated by a fusion of gm-csf and il-21 induces tumor-antigen-specific immunity. J Immunol 185(12):7358-7366. doi:10.4049/jimmunol.1002201
23. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD (2011) Type i interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208(10):1989-2003. doi:10.1084/jem.20101158
24. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF (2011) Host type i ifn signals are required for antitumor cd8 + t cell responses through cd8{alpha} + dendritic cells. J Exp Med 208(10):2005-2016. doi:10.1084/jem.20101159
25. Lesinski GB, Badgwell B, Zimmerer J, Crespin T, Hu Y, Abood G, Carson WE 3rd (2004) Il-12 pretreatments enhance ifn-alpha-induced janus kinase-stat signaling and potentiate the antitumor eVects of ifn-alpha in a murine model of malignant melanoma. J Immunol 172(12):7368-7376. doi:172/12/7368
26. Mellor AL, Munn DH (2004) Ido expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4(10):762-774 (Pubitemid 39336293)
27. Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB, Gabrilovich D (2011) Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic t cells in mice. J Clin Invest 121(10):4015-4029
28. Mellman I, Coukos G, DranoV G (2011) Cancer immunotherapy comes to age. Nature 480 (480-489)